Intravitreal Bevacizumab for Diabetic Macular Edema

Summary

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications